9月17日 - ** 美国生物技术公司Celcuity（CELC.O）股价在盘前交易中上涨2.3%，至84.50美元
** 摩根大通首次覆盖该股，给予“增持”评级；目标价157美元** 称该评级“源于Revtorpyk在乳腺癌治疗领域的长期潜力”
** 并补充称：“我们认为该模型中存在多个长期上行驱动因素，包括Revtorpyk在二线治疗（second-line treatment）领域的渗透率提升与应用范围扩大、一线治疗领域的潜力，以及潜在适应症的扩展。”
** 该公司公布 (link) 第二季度亏损幅度小于预期
** 截至昨日收盘，该公司股价年内累计下跌17.2%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.